

# Bruno Ledergerber

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5689071/publications.pdf>

Version: 2024-02-01

221  
papers

21,769  
citations

15880

67  
h-index

10679

143  
g-index

225  
all docs

225  
docs citations

225  
times ranked

17163  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Telomere Length Declines in Persons With Human Immunodeficiency Virus Before Antiretroviral Therapy Start but Not After Viral Suppression: A Longitudinal Study Over &gt;17 Years. <i>Journal of Infectious Diseases</i> , 2022, 225, 1581-1591.  | 1.9 | 3         |
| 2  | A Treatment-as-Prevention Trial to Eliminate Hepatitis C Among Men Who Have Sex With Men Living With Human Immunodeficiency Virus (HIV) in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e2194-e2202.   | 2.9 | 47        |
| 3  | Telomere Length, Traditional Risk Factors, Factors Related to Human Immunodeficiency Virus (HIV) and Coronary Artery Disease Events in Swiss Persons Living With HIV. <i>Clinical Infectious Diseases</i> , 2021, 73, e2070-e2076.  | 2.9 | 7         |
| 4  | Open wounds and rifampicin therapy are associated with rifampicin resistance among staphylococcal vascular graft/endo graft infections. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab041.   | 0.9 | 2         |
| 5  | The influence of human genetic variation on Epstein-Barr virus sequence diversity. <i>Scientific Reports</i> , 2021, 11, 4586.  | 1.6 | 8         |
| 6  | PET/CT in therapy control of infective native aortic aneurysms. <i>Scientific Reports</i> , 2021, 11, 5065.   | 1.6 | 9         |
| 7  | Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV. <i>Annals of Internal Medicine</i> , 2021, 174, 758-767.  | 2.0 | 66        |
| 8  | Impact of Delaying Antiretroviral Treatment During Primary Human Immunodeficiency Virus Infection on Telomere Length. <i>Journal of Infectious Diseases</i> , 2021, , .   | 1.9 | 2         |
| 9  | Coronary Artery Disease-Associated and Longevity-Associated Polygenic Risk Scores for Prediction of Coronary Artery Disease Events in Persons Living With Human Immunodeficiency Virus: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 1597-1604.                                | 2.9 | 5         |
| 10 | Impact of unknown incidental findings in PET/CT examinations of patients with proven or suspected vascular graft or endo graft infections. <i>Scientific Reports</i> , 2021, 11, 13747.   | 1.6 | 6         |
| 11 | PET/CT helps to determine treatment duration in patients with resected as well as inoperable alveolar echinococcosis. <i>Parasitology International</i> , 2021, 83, 102356.   | 0.6 | 12        |
| 12 | Editor's Choice - Validation of the Management of Aortic Graft Infection Collaboration (MAGIC) Criteria for the Diagnosis of Vascular Graft/Endo graft Infection: Results from the Prospective Vascular Graft Cohort Study. <i>European Journal of Vascular and Endovascular Surgery</i> , 2021, 62, 251-257. | 0.8 | 22        |
| 13 | Neurocognitive course at two-year follow-up in the neurocognitive assessment in the metabolic and aging cohort (NAMACO) study. <i>Aids</i> , 2021, Publish Ahead of Print, 2469-2480.   | 1.0 | 6         |
| 14 | Validation of the Management of Aortic Graft Infection Collaboration (MAGIC) Criteria for the Diagnosis of Vascular Graft/Endo graft Infection: Results from the Prospective Vascular Graft Cohort Study. <i>Journal of Vascular Surgery</i> , 2021, 74, 1046.  | 0.6 | 0         |
| 15 | A Lower CD4 Count Predicts Most Causes of Death except Cardiovascular Deaths. The Austrian HIV Cohort Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 12532.  | 1.2 | 3         |
| 16 | Longitudinal Progression of Subclinical Coronary Atherosclerosis in Swiss HIV-Positive Compared With HIV-Negative Persons Undergoing Coronary Calcium Score Scan and CT Angiography. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa438.  | 0.4 | 4         |
| 17 | Rapid Progression of Kidney Dysfunction in People Living With HIV: Use of Polygenic and Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Risk Scores. <i>Journal of Infectious Diseases</i> , 2020, 223, 2145-2153.  | 1.9 | 7         |
| 18 | Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study. <i>Journal of Infectious Diseases</i> , 2020, 222, 637-645.  | 1.9 | 22        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Diagnostic Accuracy of PET/CT and Contrast Enhanced CT in Patients With Suspected Infected Aortic Aneurysms. <i>European Journal of Vascular and Endovascular Surgery</i> , 2020, 59, 972-981.  | 0.8 | 26        |
| 20 | High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 135-138.   | 1.3 | 7         |
| 21 | Antiretroviral Drugs Associated With Subclinical Coronary Artery Disease in the Swiss Human Immunodeficiency Virus Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 70, 884-889.   | 2.9 | 11        |
| 22 | Contribution of Genetic Background and Data Collection on Adverse Events of Anti-human Immunodeficiency Virus (HIV) Drugs (D:A:D) Clinical Risk Score to Chronic Kidney Disease in Swiss HIV-infected Persons With Normal Baseline Estimated Glomerular Filtration Rate. <i>Clinical Infectious Diseases</i> , 2019, 70, 890-897. | 2.9 | 7         |
| 23 | Inadequate Perioperative Prophylaxis and Postsurgical Complications After Graft Implantation Are Important Risk Factors for Subsequent Vascular Graft Infections: Prospective Results From the Vascular Graft Infection Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 621-630.                                    | 2.9 | 23        |
| 24 | Comparing diagnostic accuracy of 18F-FDG-PET/CT, contrast enhanced CT and combined imaging in patients with suspected vascular graft infections. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1359-1368.   | 3.3 | 28        |
| 25 | Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations. <i>Clinical Infectious Diseases</i> , 2018, 67, 708-716.   | 2.9 | 34        |
| 26 | Subclinical coronary artery disease in Swiss HIV-positive and HIV-negative persons. <i>European Heart Journal</i> , 2018, 39, 2147-2154.  | 1.0 | 47        |
| 27 | Estimating the treatment effect on the treated under time-dependent confounding in an application to the Swiss HIV Cohort Study. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2018, 67, 103-125.  | 0.5 | 2         |
| 28 | Perioperative Antibiotic Prophylaxis Has No Effect on Time to Positivity and Proportion of Positive Samples: a Cohort Study of 64 <i>Cutibacterium acnes</i> Bone and Joint Infections. <i>Journal of Clinical Microbiology</i> , 2018, 56, .   | 1.8 | 11        |
| 29 | IF11. Good Early Results of Negative Pressure Wound Nonexcisional Treatment for Prosthetic Graft Infection Are Durable: It Is a Game Changer. <i>Journal of Vascular Surgery</i> , 2018, 67, e62.   | 0.6 | 0         |
| 30 | The role of FDG PET/CT in therapy control of aortic graft infection. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1987-1997.   | 3.3 | 32        |
| 31 | Hepatitis C infection and the risk of non-liver-related morbidity and mortality in HIV-positive persons in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2017, 64, ciw809.  | 2.9 | 34        |
| 32 | Dynamic Models for Estimating the Effect of HAART on CD4 in Observational Studies: Application to the Aquitaine Cohort and the Swiss HIV Cohort Study. <i>Biometrics</i> , 2017, 73, 294-304.   | 0.8 | 8         |
| 33 | Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study. <i>BMJ Open</i> , 2017, 7, e014679.   | 0.8 | 9         |
| 34 | Associations Between Antiretroviral Treatment and Avascular Bone Necrosis: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx177.   | 0.4 | 10        |
| 35 | Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw009.   | 0.4 | 20        |
| 36 | A Single Quantifiable Viral Load Is Predictive of Virological Failure in Human Immunodeficiency Virus (HIV)-Infected Patients on Combination Antiretroviral Therapy: The Austrian HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw089.  | 0.4 | 16        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Optimal Length of Cultivation Time for Isolation of <i>Propionibacterium acnes</i> in Suspected Bone and Joint Infections Is More than 7 Days. <i>Journal of Clinical Microbiology</i> , 2016, 54, 3043-3049.                     | 1.8 | 90        |
| 38 | CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART. <i>Medicine (United States)</i> , 2016, 95, e5094.  | 0.4 | 22        |
| 39 | Reasons for not starting antiretroviral therapy in HIV-1-infected individuals: a changing landscape. <i>Infection</i> , 2016, 44, 521-529.  | 2.3 | 7         |
| 40 | Contribution of Genetic Background and Clinical Risk Factors to Low-Trauma Fractures in Human Immunodeficiency Virus (HIV)-Positive Persons: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw101. | 0.4 | 5         |
| 41 | Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv108.    | 0.4 | 38        |
| 42 | The HIV care cascade in Switzerland. <i>Aids</i> , 2015, 29, 2509-2515.   | 1.0 | 72        |
| 43 | Reasons for late presentation to HIV care in Switzerland. <i>Journal of the International AIDS Society</i> , 2015, 18, 20317.   | 1.2 | 52        |
| 44 | A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients. <i>PLoS ONE</i> , 2015, 10, e0133028.                                    | 1.1 | 18        |
| 45 | Frequency of and Risk Factors for Depression among Participants in the Swiss HIV Cohort Study (SHCS). <i>PLoS ONE</i> , 2015, 10, e0140943.   | 1.1 | 40        |
| 46 | Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. <i>Journal of Infectious Diseases</i> , 2015, 212, 28-38.                            | 1.9 | 61        |
| 47 | High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between 2001 and 2013. <i>Journal of Hepatology</i> , 2015, 63, 573-580.                                 | 1.8 | 46        |
| 48 | Increased mortality after a first myocardial infarction in human immunodeficiency virus-infected patients; a nested cohort study. <i>AIDS Research and Therapy</i> , 2015, 12, 4.   | 0.7 | 15        |
| 49 | Neighbourhood socio-economic position, late presentation and outcomes in people living with HIV in Switzerland. <i>Aids</i> , 2015, 29, 231-238.  | 1.0 | 30        |
| 50 | Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, dkv257.  | 1.3 | 6         |
| 51 | Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0133879.        | 1.1 | 5         |
| 52 | Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0142923.   | 1.1 | 32        |
| 53 | Role of MicroRNA Modulation in the Interferon- $\alpha$ /Ribavirin Suppression of HIV-1 In Vivo. <i>PLoS ONE</i> , 2014, 9, e109220.  | 1.1 | 7         |
| 54 | Difference in factors associated with low-level viraemia and virological failure: results from the Austrian HIV Cohort Study. <i>Journal of the International AIDS Society</i> , 2014, 17, 19667.                                 | 1.2 | 8         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Treatment modification in HIV-Infected individuals starting antiretroviral therapy between 2011 and 2014. <i>Journal of the International AIDS Society</i> , 2014, 17, 19768.   | 1.2 | 11        |
| 56 | Antibiotic susceptibility of <i>Clostridium difficile</i> is similar worldwide over two decades despite widespread use of broad-spectrum antibiotics: an analysis done at the University Hospital of Zurich. <i>BMC Infectious Diseases</i> , 2014, 14, 607.                        | 1.3 | 29        |
| 57 | Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu040.  | 0.4 | 61        |
| 58 | The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort study. <i>CMAJ Open</i> , 2014, 2, E318-E329.  | 1.1 | 16        |
| 59 | Treatment-Naive Individuals Are the Major Source of Transmitted HIV-1 Drug Resistance in Men Who Have Sex With Men in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2014, 58, 285-294.  | 2.9 | 75        |
| 60 | Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV. <i>International Journal of Epidemiology</i> , 2014, 43, 887-896.  | 0.9 | 36        |
| 61 | Effects of Alpha Interferon Treatment on Intrinsic Anti-HIV-1 Immunity <i>in Vivo</i> . <i>Journal of Virology</i> , 2014, 88, 763-767.   | 1.5 | 29        |
| 62 | Accounting for baseline differences and measurement error in the analysis of change over time. <i>Statistics in Medicine</i> , 2014, 33, 2-16.  | 0.8 | 4         |
| 63 | Higher Risk of Incident Hepatitis C Virus Coinfection Among Men Who Have Sex With Men, in Whom the HIV Genetic Bottleneck at Transmission Was Wide. <i>Journal of Infectious Diseases</i> , 2014, 210, 1555-1561.   | 1.9 | 16        |
| 64 | Co-Trimoxazole Prophylaxis Is Associated with Reduced Risk of Incident Tuberculosis in Participants in the Swiss HIV Cohort Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2363-2368.  | 1.4 | 34        |
| 65 | Prevalence and Predictors for Homo- and Heterosubtypic Antibodies Against Influenza A Virus. <i>Clinical Infectious Diseases</i> , 2014, 59, 1386-1393.   | 2.9 | 9         |
| 66 | CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. <i>Aids</i> , 2013, 27, 907-918.   | 1.0 | 12        |
| 67 | Predictors of CD4+ T-Cell Counts of HIV Type 1-Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. <i>Journal of Infectious Diseases</i> , 2013, 207, 759-767.  | 1.9 | 7         |
| 68 | Antiretroviral Drug-Related Liver Mortality Among HIV-Positive Persons in the Absence of Hepatitis B or C Virus Coinfection: The Data Collection on Adverse Events of Anti-HIV Drugs Study. <i>Clinical Infectious Diseases</i> , 2013, 56, 870-879.                                | 2.9 | 42        |
| 69 | Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 28-35.                                     | 0.9 | 86        |
| 70 | Response to Calcagno Comment on "Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid". <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, e14-e15. | 0.9 | 1         |
| 71 | Cobas Ampliprep/Cobas TaqMan HIV-1 v2.0 Assay: Consequences at the Cohort Level. <i>PLoS ONE</i> , 2013, 8, e74024.   | 1.1 | 12        |
| 72 | Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. <i>International Journal of Epidemiology</i> , 2012, 41, 1807-1820.   | 0.9 | 34        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Role of retroviral restriction factors in the interferon- $\lambda$ -mediated suppression of HIV-1 in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3035-3040.  | 3.3 | 129       |
| 74 | Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection. Archives of Internal Medicine, 2012, 172, 1313.   | 4.3 | 31        |
| 75 | Incidence of HIV-1 Drug Resistance Among Antiretroviral Treatment-Naive Individuals Starting Modern Therapy Combinations. Clinical Infectious Diseases, 2012, 54, 131-140.  | 2.9 | 32        |
| 76 | Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission. Aids, 2012, 26, 193-205.   | 1.0 | 78        |
| 77 | Long-term exposure to combination antiretroviral therapy and risk of death from specific causes. Aids, 2012, 26, 315-323.   | 1.0 | 35        |
| 78 | Effect of Hepatitis C Treatment on Cd4 <sup>+</sup> T-C El L Counts And The Risk Of Death In HIV-HCV-Coinfected Patients: The Cohere Collaboration. Antiviral Therapy, 2012, 17, 1541-1550.   | 0.6 | 7         |
| 79 | Polymorphic Mutations Associated With the Emergence of the Multinucleoside/Tide Resistance Mutations 69 Insertion and Q151M. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 105-112.   | 0.9 | 9         |
| 80 | Effect of Acetazolamide and AutoCPAP Therapy on Breathing Disturbances Among Patients With Obstructive Sleep Apnea Syndrome Who Travel to Altitude. JAMA - Journal of the American Medical Association, 2012, 308, 2390.  | 3.8 | 84        |
| 81 | Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infectious Diseases, The, 2012, 12, 119-127.  | 4.6 | 41        |
| 82 | Predictive Cross-validation for the Choice of Linear Mixed-Effects Models with Application to Data from the Swiss HIV Cohort Study. Biometrics, 2012, 68, 53-61.  | 0.8 | 8         |
| 83 | Minor Protease Inhibitor Mutations at Baseline Do Not Increase the Risk for a Virological Failure in HIV-1 Subtype B Infected Patients. PLoS ONE, 2012, 7, e37983.  | 1.1 | 15        |
| 84 | Inflammation, Coagulation and Cardiovascular Disease in HIV-Infected Individuals. PLoS ONE, 2012, 7, e44454.  | 1.1 | 456       |
| 85 | Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens. PLoS ONE, 2012, 7, e50307.  | 1.1 | 16        |
| 86 | Causality, Mediation and Time: A Dynamic Viewpoint. Journal of the Royal Statistical Society Series A: Statistics in Society, 2012, 175, 831-861.   | 0.6 | 70        |
| 87 | Outcomes of Antiretroviral Therapy in the Swiss HIV Cohort Study: Latent Class Analysis. AIDS and Behavior, 2012, 16, 245-255.  | 1.4 | 20        |
| 88 | Calendar Time Trends in the Incidence and Prevalence of Triple-Class Virologic Failure in Antiretroviral Drug-Experienced People With HIV in Europe. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 294-299.                                     | 0.9 | 13        |
| 89 | Changes in Inflammatory and Coagulation Biomarkers: A Randomized Comparison of Immediate versus Deferred Antiretroviral Therapy in Patients With HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 36-43.                            | 0.9 | 142       |
| 90 | Viral Suppression Rates in Salvage Treatment With Raltegravir Improved With the Administration of Genotypic Partially Active or Inactive Nucleoside/Tide Reverse Transcriptase Inhibitors. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 24-31. | 0.9 | 23        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | A Standardized Algorithm for Determining the Underlying Cause of Death in HIV Infection as AIDS or non-AIDS Related: Results from the EuroSIDA Study. <i>HIV Clinical Trials</i> , 2011, 12, 109-117.   | 2.0 | 29        |
| 92  | Analyzing direct and indirect effects of treatment using dynamic path analysis applied to data from the Swiss HIV Cohort Study. <i>Statistics in Medicine</i> , 2011, 30, 2947-2958.  | 0.8 | 12        |
| 93  | No Longitudinal Mitochondrial DNA Sequence Changes in HIV-infected Individuals With and Without Lipotrophy. <i>Journal of Infectious Diseases</i> , 2011, 203, 620-624.   | 1.9 | 11        |
| 94  | Predictors for the Emergence of the 2 Multi-nucleoside/nucleotide Resistance Mutations 69 Insertion and Q151M and their Impact on Clinical Outcome in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2011, 203, 791-797. | 1.9 | 9         |
| 95  | The Role of Migration and Domestic Transmission in the Spread of HIV-1 Non-B Subtypes in Switzerland. <i>Journal of Infectious Diseases</i> , 2011, 204, 1095-1103.   | 1.9 | 74        |
| 96  | Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection. <i>Gut</i> , 2011, 60, 1506-1519.   | 6.1 | 60        |
| 97  | Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2011, 53, 1130-1139.   | 2.9 | 525       |
| 98  | Noncirrhotic Portal Hypertension and Didanosine: A Re-Analysis. <i>Clinical Infectious Diseases</i> , 2011, 52, 154-155.  | 2.9 | 17        |
| 99  | Improved Virological Outcome in White Patients Infected With HIV-1 Non-B Subtypes Compared to Subtype B. <i>Clinical Infectious Diseases</i> , 2011, 53, 1143-1152.   | 2.9 | 53        |
| 100 | Association of Pharmacogenetic Markers with Premature Discontinuation of First-line Anti-HIV Therapy: An Observational Cohort Study. <i>Journal of Infectious Diseases</i> , 2011, 203, 246-257.  | 1.9 | 89        |
| 101 | Ambiguous Nucleotide Calls From Population-based Sequencing of HIV-1 are a Marker for Viral Diversity and the Age of Infection. <i>Clinical Infectious Diseases</i> , 2011, 52, 532-539.  | 2.9 | 127       |
| 102 | Estimating Loss to Follow-Up in HIV-Infected Patients on Antiretroviral Therapy: The Effect of the Competing Risk of Death in Zambia and Switzerland. <i>PLoS ONE</i> , 2011, 6, e27919.  | 1.1 | 54        |
| 103 | Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years. <i>Archives of Internal Medicine</i> , 2010, 170, 410-419.  | 4.3 | 42        |
| 104 | High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naïve and successfully treated Swiss HIV patients. <i>Aids</i> , 2010, 24, 1127-1134.   | 1.0 | 159       |
| 105 | Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2010, 15, 413-423.   | 0.6 | 172       |
| 106 | Estimated average annual rate of change of CD4+ T-cell counts in patients on combination antiretroviral therapy. <i>Antiviral Therapy</i> , 2010, 15, 563-570.  | 0.6 | 12        |
| 107 | HBV or HCV Coinfections and Risk of Myocardial Infarction in HIV-Infected Individuals: The D:A:D Cohort Study. <i>Antiviral Therapy</i> , 2010, 15, 1077-1086.  | 0.6 | 35        |
| 108 | Treatment Modification in Human Immunodeficiency Virus-Infected Individuals Starting Combination Antiretroviral Therapy Between 2005 and 2008. <i>Archives of Internal Medicine</i> , 2010, 170, 57.  | 4.3 | 127       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | A sequential Cox approach for estimating the causal effect of treatment in the presence of time-dependent confounding applied to data from the Swiss HIV Cohort Study. <i>Statistics in Medicine</i> , 2010, 29, 2757-2768.                          | 0.8 | 61        |
| 110 | ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 217-230.  | 0.7 | 104       |
| 111 | Different Patterns of Inappropriate Antimicrobial Use in Surgical and Medical Units at a Tertiary Care Hospital in Switzerland: A Prevalence Survey. <i>PLoS ONE</i> , 2010, 5, e14011.  | 1.1 | 85        |
| 112 | Frequency and Determinants of Unprotected Sex among HIV-Infected Persons: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2010, 51, 1314-1322.   | 2.9 | 83        |
| 113 | Impact of Single Nucleotide Polymorphisms and of Clinical Risk Factors on New-Onset Diabetes Mellitus in HIV-Infected Individuals. <i>Clinical Infectious Diseases</i> , 2010, 51, 1090-1098.  | 2.9 | 26        |
| 114 | Epidemiological and Biological Evidence for a Compensatory Effect of Connection Domain Mutation N348I on M184V in HIV-1 Reverse Transcriptase. <i>Journal of Infectious Diseases</i> , 2010, 201, 1054-1062.   | 1.9 | 27        |
| 115 | Reply to Chang and Garcia-Pagan. <i>Clinical Infectious Diseases</i> , 2010, 50, 128-129.  | 2.9 | 3         |
| 116 | Molecular Epidemiology Reveals Long-Term Changes in HIV Type 1 Subtype B Transmission in Switzerland. <i>Journal of Infectious Diseases</i> , 2010, 201, 1488-1497.  | 1.9 | 172       |
| 117 | HIV-1 Reverse Transcriptase Connection Domain Mutations: Dynamics of Emergence and Implications for Success of Combination Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2010, 51, 620-628.  | 2.9 | 26        |
| 118 | Incidence and Risk Factors for Chronic Elevation of Alanine Aminotransferase Levels in HIV-Infected Persons without Hepatitis B or C Virus Co-Infection. <i>Clinical Infectious Diseases</i> , 2010, 50, 502-511.                                    | 2.9 | 88        |
| 119 | Cohort Profile: The Swiss HIV Cohort Study. <i>International Journal of Epidemiology</i> , 2010, 39, 1179-1189.  | 0.9 | 322       |
| 120 | Reply to Kuniholm et al. <i>Clinical Infectious Diseases</i> , 2010, 50, 1546-1547.  | 2.9 | 0         |
| 121 | Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. <i>Aids</i> , 2010, 24, 1667-1678.  | 1.0 | 353       |
| 122 | Implementation of Raltegravir in Routine Clinical Practice: Selection Criteria for Choosing This Drug, Virologic Response Rates, and Characteristics of Failures. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 53, 464-471. | 0.9 | 17        |
| 123 | Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 262-270.   | 0.9 | 243       |
| 124 | Death rates in HIV-positive antiretroviral-naïve patients with CD4 count greater than 350 cells per $\hat{1}/4$ L in Europe and North America: a pooled cohort observational study. <i>Lancet, The</i> , 2010, 376, 340-345.                         | 6.3 | 82        |
| 125 | Risk factors for urinary tract infections due to ciprofloxacin-resistant <i>Escherichia coli</i> in a tertiary care urology department in Switzerland. <i>Swiss Medical Weekly</i> , 2010, 140, w13059.  | 0.8 | 21        |
| 126 | Association of Noncirrhotic Portal Hypertension in HIV-Infected Persons and Antiretroviral Therapy with Didanosine: A Nested Case-Control Study. <i>Clinical Infectious Diseases</i> , 2009, 49, 626-635.  | 2.9 | 117       |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 127 | Common Genetic Variation and the Control of HIV-1 in Humans. <i>PLoS Genetics</i> , 2009, 5, e1000791.   | 1.5 | 377       |
| 128 | Long-Term Trends of HIV Type 1 Drug Resistance Prevalence among Antiretroviral Treatment-Experienced Patients in Switzerland. <i>Clinical Infectious Diseases</i> , 2009, 48, 979-987.                                   | 2.9 | 43        |
| 129 | Contribution of Genome-Wide Significant Single-Nucleotide Polymorphisms and Antiretroviral Therapy to Dyslipidemia in HIV-Infected Individuals. <i>Circulation: Cardiovascular Genetics</i> , 2009, 2, 621-628.          | 5.1 | 38        |
| 130 | Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. <i>Lancet, The</i> , 2009, 373, 1352-1363.                                       | 6.3 | 676       |
| 131 | African descent is associated with slower CD4 cell count decline in treatment-naïve patients of the Swiss HIV Cohort Study. <i>Aids</i> , 2009, 23, 1269-1276.   | 1.0 | 28        |
| 132 | Hepatitis C Virus Coinfection Does Not Influence the CD4 Cell Recovery in HIV-1-Infected Patients With Maximum Virologic Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 50, 457-463. | 0.9 | 49        |
| 133 | Impact of Previous Virological Treatment Failures and Adherence on the Outcome of Antiretroviral Therapy in 2007. <i>PLoS ONE</i> , 2009, 4, e8275.  | 1.1 | 18        |
| 134 | HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy. <i>Aids</i> , 2008, 22, 469-479.  | 1.0 | 59        |
| 135 | Durability and Outcome of Initial Antiretroviral Treatments Received during 2000-2005 by Patients in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2008, 197, 1685-1694.                           | 1.9 | 95        |
| 136 | Factors Associated with the Emergence of K65R in Patients with HIV-1 Infection Treated with Combination Antiretroviral Therapy Containing Tenofovir. <i>Clinical Infectious Diseases</i> , 2008, 46, 1299-1309.          | 2.9 | 35        |
| 137 | Stratification of cumulative antibiograms in hospitals for hospital unit, specimen type, isolate sequence and duration of hospital stay. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1451-1461.             | 1.3 | 46        |
| 138 | Correlation between case mix index and antibiotic use in hospitals. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 837-842.  | 1.3 | 66        |
| 139 | Spontaneous Viral Clearance, Viral Load, and Genotype Distribution of Hepatitis C Virus (HCV) in HIV-Infected Patients with Anti-HCV Antibodies in Europe. <i>Journal of Infectious Diseases</i> , 2008, 198, 1337-1344. | 1.9 | 145       |
| 140 | Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons. <i>Aids</i> , 2008, 22, 767-775.  | 1.0 | 48        |
| 141 | Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. <i>Aids</i> , 2008, 22, 2135-2141.  | 1.0 | 145       |
| 142 | Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection. <i>PLoS Medicine</i> , 2008, 5, e203.  | 3.9 | 1,398     |
| 143 | Public-Health and Individual Approaches to Antiretroviral Therapy: Township South Africa and Switzerland Compared. <i>PLoS Medicine</i> , 2008, 5, e148.   | 3.9 | 113       |
| 144 | Factors Associated with the Incidence of Type 2 Diabetes Mellitus in HIV-Infected Participants in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2007, 45, 111-119.                                   | 2.9 | 233       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 145 | Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. <i>Aids</i> , 2007, 21, 2223-2229.   | 1.0 | 117       |
| 146 | A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men. <i>International Journal of Epidemiology</i> , 2007, 36, 1309-1318.   | 0.9 | 22        |
| 147 | Emergence of HIV-1 Drug Resistance in Previously Untreated Patients Initiating Combination Antiretroviral Treatment<sub>title</sub>&gt;A Comparison of Different Regimen Types</sub>&gt;. <i>Archives of Internal Medicine</i> , 2007, 167, 1782. | 4.3 | 116       |
| 148 | Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score. <i>Aids</i> , 2007, 21, 1867-1875.   | 1.0 | 38        |
| 149 | Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. <i>Aids</i> , 2007, 21, 1185-1197.   | 1.0 | 264       |
| 150 | A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1. <i>Science</i> , 2007, 317, 944-947.  | 6.0 | 1,136     |
| 151 | Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing in HIV-Infected Patients with Treatment Failure. <i>PLoS ONE</i> , 2007, 2, e173.   | 1.1 | 31        |
| 152 | Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. <i>Aids</i> , 2006, 20, 1141-1150.  | 1.0 | 39        |
| 153 | Stable virulence levels in the HIV epidemic of Switzerland over two decades. <i>Aids</i> , 2006, 20, 889-894.   | 1.0 | 52        |
| 154 | Factors Associated with the Development of Opportunistic Infections in HIV-1-Infected Adults with High CD4+Cell Counts: A EuroSIDA Study. <i>Journal of Infectious Diseases</i> , 2006, 194, 633-641.   | 1.9 | 70        |
| 155 | Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus. <i>Archives of Internal Medicine</i> , 2006, 166, 1632.   | 4.3 | 1,004     |
| 156 | A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?. <i>Antiviral Therapy</i> , 2006, 11, 305-14.                                    | 0.6 | 4         |
| 157 | A Longitudinal Analysis of Healthcare Costs after Treatment Optimization following Genotypic Antiretroviral Resistance Testing: Does Resistance Testing pay off?. <i>Antiviral Therapy</i> , 2006, 11, 305-314.                                   | 0.6 | 10        |
| 158 | Impact of Lamivudine on the Risk of Liver-Related Death in 2,041 Hbsag- and HIV-Positive Individuals: Results from An Inter-Cohort Analysis. <i>Antiviral Therapy</i> , 2006, 11, 567-574.  | 0.6 | 38        |
| 159 | Eligibility for and Outcome of Hepatitis C Treatment of HIV-Coinfected Individuals in Clinical Practice: The Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2006, 11, 131-142.  | 0.6 | 35        |
| 160 | Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. <i>Aids</i> , 2005, 19, 1987-1994.   | 1.0 | 29        |
| 161 | The Changing Incidence of AIDS Events in Patients Receiving Highly Active Antiretroviral Therapy. <i>Archives of Internal Medicine</i> , 2005, 165, 416.  | 4.3 | 124       |
| 162 | Modeling the Influence ofAPOC3, APOE,andTNFPolymorphisms on the Risk of Antiretroviral Therapy-Associated Lipid Disorders. <i>Journal of Infectious Diseases</i> , 2005, 191, 1419-1426.  | 1.9 | 105       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 163 | Risk Factors for and Outcome of Hyperlactatemia in HIV-Infected Persons: Is There a Need for Routine Lactate Monitoring?. <i>Clinical Infectious Diseases</i> , 2005, 41, 721-728.   | 2.9 | 36        |
| 164 | Characteristics, Determinants, and Clinical Relevance of CD4 T Cell Recovery to <500 Cells/ÅL in HIV Type 1-Infected Individuals Receiving Potent Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2005, 41, 361-372. | 2.9 | 285       |
| 165 | Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. <i>Aids</i> , 2005, 19, 593-601.   | 1.0 | 472       |
| 166 | Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. <i>Lancet, The</i> , 2005, 366, 378-384.  | 6.3 | 526       |
| 167 | Influence of Hepatitis C Virus Infection on HIV Disease Progression and Response to Highly Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2005, 192, 992-1002.   | 1.9 | 362       |
| 168 | Thymidine Analogue Mutation Profiles: Factors Associated with Acquiring Specific Profiles and their Impact on the Virological Response to Therapy. <i>Antiviral Therapy</i> , 2005, 10, 791-802.                                   | 0.6 | 55        |
| 169 | Pulmonary Arterial Hypertension Related to HIV Infection: Improved Hemodynamics and Survival Associated with Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2004, 38, 1178-1185.                                    | 2.9 | 186       |
| 170 | Antiretroviral Treatment and Osteonecrosis in Patients of the Swiss HIV Cohort Study: A Nested Case-Control Study. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 909-915.  | 0.5 | 28        |
| 171 | Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. <i>Lancet, The</i> , 2004, 364, 51-62.                          | 6.3 | 303       |
| 172 | Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. <i>Aids</i> , 2004, 18, 1795-1804.   | 1.0 | 26        |
| 173 | Causes of death in HIV infection. <i>Aids</i> , 2004, 18, 2333-2337.   | 1.0 | 34        |
| 174 | Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine. <i>Aids</i> , 2004, 18, 2213-2215.  | 1.0 | 14        |
| 175 | HIV cohort collaborations: proposal for harmonization of data exchange. <i>Antiviral Therapy</i> , 2004, 9, 631-3.   | 0.6 | 16        |
| 176 | Effect of Individual Cognitive Behaviour Intervention on Adherence to Antiretroviral Therapy: Prospective Randomized Trial. <i>Antiviral Therapy</i> , 2004, 9, 85-95.   | 0.6 | 61        |
| 177 | Long-Term Virological Response to Multiple Sequential Regimens of Highly Active Antiretroviral Therapy for HIV Infection. <i>Antiviral Therapy</i> , 2004, 9, 263-274.   | 0.6 | 11        |
| 178 | HIV Cohort Collaborations: Proposal for Harmonization of Data Exchange. <i>Antiviral Therapy</i> , 2004, 9, 631-633.   | 0.6 | 33        |
| 179 | Baseline Resistance and Virological Outcome in Patients with Virological Failure who Start a Regimen Containing Abacavir: EuroSIDA Study. <i>Antiviral Therapy</i> , 2004, 9, 787-800.   | 0.6 | 7         |
| 180 | Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. <i>Lancet, The</i> , 2003, 362, 877-878.  | 6.3 | 101       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 181 | CD4 T-Lymphocyte Recovery in Individuals With Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years<subtitle>The Swiss HIV Cohort Study</subtitle>. Archives of Internal Medicine, 2003, 163, 2187.       | 4.3 | 344       |
| 182 | HIV-1 p24 Antigen Is a Significant Inverse Correlate of CD4 T-Cell Change in Patients With Suppressed Viremia Under Long-Term Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 292-299. | 0.9 | 41        |
| 183 | Virological rebound after suppression on highly active antiretroviral therapy. Aids, 2003, 17, 1741-1751.  | 1.0 | 99        |
| 184 | Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study. Aids, 2003, 17, 2237-2244.   | 1.0 | 76        |
| 185 | Impact of genotypic resistance testing on selection of salvage regimen in clinical practice. Antiviral Therapy, 2003, 8, 443-54.   | 0.6 | 8         |
| 186 | Changes in Viral Load in People with Virological Failure who Remain on the Same Haart Regimen. Antiviral Therapy, 2003, 8, 127-136.  | 0.6 | 24        |
| 187 | Impact of Genotypic Resistance Testing on Selection of Salvage Regimen in Clinical Practice. Antiviral Therapy, 2003, 8, 443-454.  | 0.6 | 23        |
| 188 | Association of Virus Load, CD4 Cell Count, and Treatment with Clinical Progression in Human Immunodeficiency Virusâ€“Infected Patients with Very Low CD4 Cell Counts. Journal of Infectious Diseases, 2002, 186, 189-197.        | 1.9 | 52        |
| 189 | Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a caseâ€“control study from the Swiss HIV Cohort. Aids, 2002, 16, 381-385.   | 1.0 | 31        |
| 190 | A Clinically Prognostic Scoring System for Patients Receiving Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study. Journal of Infectious Diseases, 2002, 185, 178-187.   | 1.9 | 116       |
| 191 | A Randomized Trial of Simplified Maintenance Therapy with Abacavir, Lamivudine, and Zidovudine in Human Immunodeficiency Virus Infection. Journal of Infectious Diseases, 2002, 185, 1251-1260.                                  | 1.9 | 132       |
| 192 | Safe Interruption of Maintenance Therapy against Previous Infection with Four Common HIV-Associated Opportunistic Pathogens during Potent Antiretroviral Therapy. Annals of Internal Medicine, 2002, 137, 239.                   | 2.0 | 122       |
| 193 | Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 Å— 106/l. Aids, 2002, 16, 1371-1381.   | 1.0 | 105       |
| 194 | Impact of occasional short interruptions of HAART on the progression of HIV infection: results from a cohort study. Aids, 2002, 16, 747-755.   | 1.0 | 40        |
| 195 | Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet, The, 2002, 360, 119-129.  | 6.3 | 1,415     |
| 196 | Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. Aids, 2002, 16, 1967-1969.   | 1.0 | 107       |
| 197 | HIV-1 progression in hepatitis-C-infected drug users. Lancet, The, 2001, 357, 1363.  | 6.3 | 2         |
| 198 | Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet, The, 2001, 358, 1322-1327.   | 6.3 | 317       |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 199 | Importance of Mental Health Assessment in HIV-Infected Outpatients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 28, 240-249.  | 0.9  | 44        |
| 200 | Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. <i>Aids</i> , 2001, 15, 2385-2395.  | 1.0  | 61        |
| 201 | Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy The Swiss HIV Cohort Study. <i>Aids</i> , 2001, 15, 1793-1800.   | 1.0  | 39        |
| 202 | Quantification of In Vivo Replicative Capacity of HIV-1 in Different Compartments of Infected Cells. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 26, 397-404.   | 0.9  | 12        |
| 203 | Discontinuation of Secondary Prophylaxis against <i>Pneumocystis carinii</i> Pneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral Therapy. <i>New England Journal of Medicine</i> , 2001, 344, 168-174.  | 13.9 | 155       |
| 204 | Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. <i>Aids</i> , 2000, 14, 2145-2151.  | 1.0  | 30        |
| 205 | Discontinuing or withholding primary prophylaxis against <i>Mycobacterium avium</i> in patients on successful antiretroviral combination therapy. The Swiss HIV Cohort Study. <i>Aids</i> , 2000, 14, 1409-1412.   | 1.0  | 28        |
| 206 | Human Immunodeficiency Virus Type 1 p24 Concentration Measured by Boosted ELISA of Heat-Denatured Plasma Correlates with Decline in CD4 Cells, Progression to AIDS, and Survival: Comparison with Viral RNA Measurement. <i>Journal of Infectious Diseases</i> , 2000, 181, 1280-1287. | 1.9  | 73        |
| 207 | Intestinal Infection Due to Enteroaggregative <i>Escherichia coli</i> among Human Immunodeficiency Virus-Infected Persons. <i>Journal of Infectious Diseases</i> , 2000, 182, 1540-1544.   | 1.9  | 40        |
| 208 | Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. <i>Aids</i> , 1999, 13, 943-950.   | 1.0  | 335       |
| 209 | Randomized, Placebo-Controlled Trial of Chinese Herb Therapy for HIV-1-Infected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1999, 22, 56.  | 0.3  | 31        |
| 210 | AIDS-Related Opportunistic Illnesses Occurring After Initiation of Potent Antiretroviral Therapy. <i>JAMA - Journal of the American Medical Association</i> , 1999, 282, 2220.   | 3.8  | 416       |
| 211 | Incidence and Predictors of Virologic Failure of Antiretroviral Triple-Drug Therapy in a Community-Based Cohort. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 1631-1638.  | 0.5  | 79        |
| 212 | Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. <i>BMJ: British Medical Journal</i> , 1999, 319, 23-24.  | 2.4  | 208       |
| 213 | Sex differences in HIV-1 viral load and progression to AIDS. <i>Lancet, The</i> , 1999, 353, 589.  | 6.3  | 60        |
| 214 | Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. <i>Lancet, The</i> , 1999, 353, 863-868.   | 6.3  | 894       |
| 215 | Discontinuation of <i>Pneumocystis carinii</i> pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. <i>Lancet, The</i> , 1999, 353, 1293-1298.  | 6.3  | 206       |
| 216 | Regional survival differences across Europe In HIV-positive people: the EuroSIDA study. <i>Aids</i> , 1999, 13, 2281-2288.   | 1.0  | 22        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 217 | Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy. <i>Aids</i> , 1999, 13, 1587.   | 1.0 | 24        |
| 218 | Levels of HIV-infected peripheral blood cells remain stable throughout the natural history of HIV-1 infection. <i>Aids</i> , 1998, 12, 2253-2260.  | 1.0 | 36        |
| 219 | Regional Differences in Use of Antiretroviral Agents and Primary Prophylaxis in 3122 European HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1997, 16, 153-160. | 0.3 | 58        |
| 220 | The Swiss HIV Cohort Study: Rationale, organization and selected baseline characteristics. <i>International Journal of Public Health</i> , 1994, 39, 387-394.                                    | 2.7 | 138       |
| 221 | Survival in HIV infection: do sex and category of transmission matter?. <i>Aids</i> , 1994, 8, 1307-1313.  | 1.0 | 49        |